Century Therapeutics, Inc. IPSC

IPSC Company Overview

Century Therapeutics, Inc. (NASDAQ: IPSC) is a U.S.-based biotechnology company focused on developing induced pluripotent stem cell (iPSC)-derived cell therapies for oncology and autoimmune diseases. The company operates within the biotechnology, cell therapy, and immuno-oncology industries, with a primary emphasis on creating allogeneic, or “off-the-shelf,” cellular medicines designed to overcome manufacturing and scalability limitations associated with autologous therapies. Century Therapeutics’ core technology platform combines gene editing, stem cell engineering, and differentiated immune effector cells, including natural killer (NK) cells and T cells, to develop standardized therapies intended for broad patient use.

The company’s principal revenue sources historically have included collaboration agreements, research funding, and licensing arrangements rather than commercial product sales, as its therapeutic candidates remain in clinical and preclinical development. Century Therapeutics has differentiated itself through its proprietary iPSC platform, which aims to enable scalable manufacturing, genetic engineering precision, and product consistency across treatment batches. Founded in 2018, the company emerged from scientific work associated with FUJIFILM Cellular Dynamics, Inc. and has evolved through strategic partnerships and internal platform development focused on next-generation cell therapy technologies.